20231238 - Bilusic Marijo
-
Investigator:
Marijo Bilusic
Email
Coordinator:
IRB: 20231238
SDG: GU
Disease Site(s): Bladder,Kidney,Other Urinary
Sponsor: Bicycle Therapeutics
Enrolling Sites:
Aventura
Deerfield
Gables
Hollywood
Kendall
Plantation
Sylvester
UMHTitle: A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Eligibility Criteria - NCT06225596 *This information has been extracted from " www.clinicaltrials.gov"
20231239 - Bilusic Marijo
-
Investigator:
Marijo Bilusic
Email
Coordinator:
IRB: 20231239
SDG: GU
Disease Site(s): Prostate
Sponsor: MERCK SHARP & DOHME
Enrolling Sites:
Aventura
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
Sylvester
UMHTitle: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Eligibility Criteria - NCT06136624 *This information has been extracted from " www.clinicaltrials.gov"
20220783 - Gonzalgo Mark
-
Investigator:
Mark Gonzalgo
Email
Coordinator:
IRB: 20220783
SDG: GU
Disease Site(s): Kidney
Sponsor: SCCC
Enrolling Sites:
Plantation
Sylvester
UMHTitle: NSAID Use after Robotic Partial Nephrectomy (No-PAIN): a randomized, controlled trial
Eligibility Criteria - NCT05842044 *This information has been extracted from " www.clinicaltrials.gov"
20220852 - Punnen Sanoj
-
Investigator:
Sanoj Punnen
Email
Coordinator:
IRB: 20220852
SDG: GU
Disease Site(s): Prostate
Sponsor: SCCC
Enrolling Sites:
Deerfield
Sylvester
UMHTitle: Phase 2 Randomized Trial: Human Amnion Membrane Allograft and Early Return of Erectile Function after Radical Prostatectomy (HAMMER)
Eligibility Criteria - NCT05842057 *This information has been extracted from " www.clinicaltrials.gov"
20240036 - Punnen Sanoj
-
Investigator:
Sanoj Punnen
Email
Coordinator:
IRB: 20240036
SDG: GU
Disease Site(s): Prostate
Sponsor: CURIUM US LLC
Enrolling Sites:
Deerfield
Gables
Plantation
Sylvester
UMHTitle: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Eligibility Criteria - NCT06235151 *This information has been extracted from " www.clinicaltrials.gov"
SWOG S1802 - Ritch, Chad
-
Investigator:
Chad Ritch
Email
Coordinator:
IRB: 20180970
SDG: GU
Disease Site(s): Prostate
Sponsor: SWOG
Enrolling Sites:
Deerfield
Gables
SylvesterTitle: S1802: PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER
Eligibility Criteria - NCT03678025 *This information has been extracted from " www.clinicaltrials.gov"
20220331 - Ritch Chad
-
Investigator:
Chad Ritch
Email
Coordinator:
IRB: 20220331
SDG: GU
Disease Site(s): Other Male Genital
Sponsor: ECOG
Enrolling Sites:
Sylvester
Title: EA8134: InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative study)
Eligibility Criteria - NCT02305654 *This information has been extracted from " www.clinicaltrials.gov"
20231126 - Sharma Janaki
-
Investigator:
Janaki Sharma
Email
Coordinator:
IRB: 20231126
SDG: GU
Disease Site(s): Prostate
Sponsor: NCTN
Enrolling Sites:
Sylvester
Title: A Phase 2 Study of M1774 in Refractory SPOP-mutant Prostate Cancer
Eligibility Criteria - NCT05828082 *This information has been extracted from " www.clinicaltrials.gov"
20240124 - Sharma Janaki
-
Investigator:
Janaki Sharma
Email
Coordinator:
IRB: 20240124
SDG: GU
Disease Site(s): Bladder
Sponsor: NCI
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Eligibility Criteria - NCT05987241 *This information has been extracted from " www.clinicaltrials.gov"